About us

Recognized Young Innovative Company (2006) and Innovative Company (2013), winner of awards recognizing both its unique innovation capabilities (Bpifrance excellence) and high growth (Deloitte Technology Fast 50, DENA), the company has positioned itself as a key leader in characterization and preclinical development of antibacterial, antifungal, antiparasitic and prebiotic actives in all sectors.

 

SETUBIO leverages its high throughput screening platform unique in the world, to find new compounds, primarily from biodiversity (plants, fungi, algae and microalgae ...). Innovative actives resulting from research are declined on key industrial sectors of interest, namely human and animal health, and human and animal nutrition, hygiene, cosmetics, agriculture or industry.

 

The business model is based on SETUBIO three main areas: outsourcing, partnership and valuing own research.

 

In 2012, SETUBIO introduced its first active issued from his research on the American market. The ingredient, Compound FJ1, is marketed in North America as a dietary supplement.

 

In 2014, SETUBIO launched a unique range of dermo-cosmetic treatments specifically dedicated to patients who have undergone cancer treatments. The range NOLEA JOY is responding to a lack of products specifically dedicated to these patients, and developed according to the new European regulations, with scientifically recognized active plant extracts, with the aim of meeting the needs explicitly formulated by the patients. These products are no longer marketed.

 

SETUBIO's subsidiary Control and Analysis has been sold in august 2016, it was dedicated to routine analysis for quality and regulatory qualification in cosmetics, nutraceutics, medical devices, and drugs.